CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
G-CSF and plerixafordrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00322387
NCT00322387Phase 2Completed
CompareCT.gov

Treatment With Plerixafor in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients to Increase the Number of Peripheral Blood Stem Cells When Given With A Mobilizing Regimen of Chemotherapy and G-CSF

Genzyme, a Sanofi Company·interventional·Posted May 5, 2006·Updated Mar 13, 2014

In Brief

A Phase 2 clinical trial evaluating G-CSF and plerixafor for Lymphoma, Non-Hodgkin and Multiple Myeloma. Completed, enrolled 40 participants across 5 sites.

Detailed Summary

Patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) will be mobilized with chemotherapy and G-CSF plus plerixafor (AMD3100). The purpose of this protocol is to determine if plerixafor given after chemotherapy and G-CSF mobilization regimen is safe, if it can increase the circulating levels of peripheral blood stem cells (PBSCs) by ≥ 2-fold before apheresis, and if transplantation with the apheresis product was successful, as measured by time to engraftment of polymorphonuclear leukocytes (PMNs) and platelets (PLTs).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Non-Hodgkin, Multiple Myeloma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 5, 2006
Enrollment StartApr 1, 2004
Primary CompletionJul 1, 2006
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.2 years ago

Interventions

G-CSF and plerixafordrug

G-CSF and plerixafor were administered as described in the treatment arms.